Phase I Trial Shows Promise for Cimaglermin in Heart Failure

Share this content:
Phase I Trial Shows Promise for Cimaglermin in Heart Failure
Phase I Trial Shows Promise for Cimaglermin in Heart Failure

WEDNESDAY, Dec. 28, 2016 (HealthDay News) -- The recombinant growth factor, cimaglermin alfa, may enhance cardiac function in left ventricular systolic dysfunction (LVSD), according to a study published in the Dec. 1 issue of JACC: Basic to Translational Science.

Daniel J. Lenihan, M.D., from Vanderbilt University in Nashville, Tenn., and colleagues examined the safety, tolerability, and exploratory efficacy of intravenous infusion of cimaglermin alfa in a first-in-human, phase 1 single ascending dose study involving 40 patients with heart failure and LVSD.

The researchers found that cimaglermin treatment was generally well tolerated in these patients on optimal guideline-directed medical therapy, except for transient nausea and headache. At the highest planned dose, dose-limiting toxicity was noted. A dose-dependent improvement was seen in left ventricular ejection fraction, which lasted 90 days after infusion.

"Thus, cimaglermin is a potential therapy to enhance cardiac function in LVSD and warrants further investigation," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Acorda Therapeutics, which is developing cimaglermin alfa and funded the study.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trials Highlight Benefits, Risks of Testosterone Treatment

Trials Highlight Benefits, Risks of Testosterone Treatment

While trials show it boosts bone density and lowers anemia risk, heart risks also seen

Exercise Most Important Lifestyle Change for Breast CA Survivors

Exercise Most Important Lifestyle Change for Breast CA ...

Those who exercised were about 40 percent less likely to die from disease, review suggests

CMS Rule Set to Stabilize Small Health Insurance Markets

CMS Rule Set to Stabilize Small Health Insurance ...

Rule includes special enrollment period pre-enrollment verification, flexibility in level of cover

is free, fast, and customized just for you!

Already a member?

Sign In Now »